Table 1. Participants’ demographics and HIV-related characteristics, Île-de-France, France, May 2021–June 2022 (n = 1,159).
| Characteristic | All participants (n = 1,159) |
Participants who completed the questionnaire (n = 831) |
|---|---|---|
| Value | Value | |
| Age in years at study inclusion, median (IQR) | 43 (34–56) | 43 (34–55) |
| Place of birth, n (%) | ||
| Latin America | 336 (29.0%) | 275 (33.1%) |
| Europe | 244 (21.1%) | 175 (21.1%) |
| North Africa | 187 (16.1%) | 114 (13.7%) |
| Sub-Saharan Africa | 180 (15.5%) | 119 (14.3%) |
| Asia, Oceania | 174 (15.0%) | 116 (14.0%) |
| North America | 38 (3.3%) | 32 (3.9%) |
| Age in years at arrival in France, median (IQR) | 25 (20–31) | 27 (23–32) |
| Age at arrival in France, n (%) | ||
| < 15 years | 165 (14.2%) | 0 (0.0%) |
| 15–20 years | 143 (12.3%) | 121 (14.6%) |
| 21–25 years | 282 (24.3%) | 229 (27.6%) |
| 26–30 years | 259 (22.3%) | 216 (26.0%) |
| > 30 years | 310 (26.7%) | 265 (31.9%) |
| Time in years from first HIV medical visit in France, median (IQR) | 5.9 (2.8–11.8) | 5.4 (2.6–11.1) |
| Time in years from HIV diagnosis, median (IQR) | 8.9 (5.1–18.1) | 8.5 (4.9–16.6) |
| Hepatitis B co-infection (positive AgHBS), n (%) | 63 (5.4%) | 46 (5.5%) |
| Hepatitis C co-infection (positive anti-HCV Ab), n (%) | 84 (7.2%) | 58 (7.0%) |
| AIDS-event at care entrya, n (%) | 65 (5.6%) | 45 (5.4%) |
| First CD4+ T-cell count (in cells/mm3) available in France, median (IQR) | 400 (246–604) | 401 (250–609) |
| First plasma viral load available in France, n (%) | ||
| ≥ 50 copies/mL | 861 (74.3%) | 609 (73.3%) |
| < 50 copies/mL | 168 (14.5%) | 125 (15.0%) |
| Missing | 130 (11.2%) | 97 (11.7%) |
AIDS: acquired-immunodeficiency syndrome; IQR: interquartile range.
a Opportunistic disease diagnosed in the 6 months before or after the first HIV medical visit in France.